Foster Jill A, Perry Julian D, Cahill Kenneth V, Holck David E E, Kugler Lance
Grant Eye and Ear Hospital, the Ohio State University, Columbus, Ohio 44195, USA.
Ophthalmic Plast Reconstr Surg. 2004 Mar;20(2):107-9. doi: 10.1097/01.iop.0000117336.36374.9b.
To determine the safety and efficacy of processed human pericardium as a barrier material for gold weight implantation.
In this retrospective, noncomparative case series, all patients undergoing gold weight implantation with human pericardium barrier between November 2000 and May 2002 were studied. Charts were reviewed for surgical indications, gold weight size, follow-up interval, and complications.
Twenty-three eyelids of 23 patients underwent gold weight implantation with processed human pericardium barrier material. There were 15 female and 8 male patients. Mean patient age was 53 years (range, 22 to 78 years). Indications for surgery included extruded implant (4 eyelids), thin tissues overlying existing implant (3 eyelids), thin anterior lamellar eyelid tissues (6 eyelids), radiotherapy (1 eyelid), and requirement for long-term gold weight therapy (9 eyelids). Mean follow-up was 11 months (range, 3 to 36 months). Acceptable tissue coverage was found in 23 of 23 eyelids. There were no complications of infection, extrusion, or thinning of overlying tissues. One patient had prolonged eyelid edema and erythema that resolved spontaneously 3 months after surgery.
Human pericardium appears to be well tolerated on at least a short-term basis within the eyelid when used as a barrier material for gold weight implantation.
确定经处理的人心包作为金片植入屏障材料的安全性和有效性。
在这个回顾性、非对照病例系列研究中，对2000年11月至2002年5月期间所有使用人心包屏障进行金片植入的患者进行了研究。查阅病历以了解手术指征、金片大小、随访间隔和并发症情况。
23例患者的23只眼睑使用经处理的人心包屏障材料进行了金片植入。其中女性15例，男性8例。患者平均年龄为53岁（范围22至78岁）。手术指征包括植入物外露（4只眼睑）、覆盖现有植入物的组织过薄（3只眼睑）、眼睑前层组织过薄（6只眼睑）、放疗（1只眼睑）以及长期金片治疗需求（9只眼睑）。平均随访时间为11个月（范围3至36个月）。23只眼睑中有23只获得了可接受的组织覆盖。没有感染、植入物外露或覆盖组织变薄的并发症。1例患者出现了眼睑水肿和红斑延长，术后3个月自行消退。
当用作金片植入的屏障材料时，人心包在眼睑内至少短期内似乎耐受性良好。
